Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection

Pharmacogenomics

Volumn 16, Issue 10, 2015, Pages 1179-1188

  Rembeck, Karolina ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Genetic variant; HCV; histology; IL28B; inosine triphosphate pyrophosphatase; interferon ; ITPA; ITPase; natural history; PNPLA3; therapy

Indexed keywords

ALPHA INTERFERON; DELEOBUVIR; FALDAPREVIR; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; INTERFERON; INTERFERON LAMBDA4 GENE; INTERFERON REGULATORY FACTOR; INTERLEUKIN 28B; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PEGINTERFERON ALPHA; PHOSPHOLIPASE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VIRUS RNA; ADIPONUTRIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; ITPA PROTEIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ALLELE; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HISTOPATHOLOGY; HUMAN; IL28B GENE; ITPA GENE; LIVER FIBROSIS; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PNPLA3 GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; DISEASE COURSE; GENETIC VARIATION; GENETICS; HEPACIVIRUS; PATHOGENICITY; VIROLOGY;

DISEASE PROGRESSION; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; LIPASE; MEMBRANE PROTEINS; PYROPHOSPHATASES;

EID: 84941649088     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.65     Document Type: Review

References (83)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
2. Robertson B, Myers G, Howard C et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143(12), 2493-2503 (1998).
3. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42(4), 962-973 (2005).
4. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74(Pt 11), 2391-2399 (1993).
5. Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59(1), 318-327 (2014).
6. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12(4 Pt 1), 671-675 (1990).
7. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332(22), 1463-1466 (1995).
8. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6, 664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 26(2), 485-490 (1997).
9. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
10. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
11. Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139(5), 1586-1592, 1592 e1581 (2010).
12. Bochud PY, Bibert S, Negro F et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J. Hepatol. 55(5), 980-988 (2011).
13. Stenkvist J, Sonnerborg A, Weiland O. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. J. Viral Hepat. 20(3), 193-199 (2013).
14. Sarrazin C, Susser S, Doehring A et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 54(3), 415-421 (2011).
15. Mccarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138(7), 2307-2314 (2010).
16. Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53(3), 746-754 (2011).
17. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345, 1345 e1331-1337 (2010).
18. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
19. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
20. Poordad F, Bronowicki JP, Gordon SC et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 143(3), 608-618, e601-605 (2012).
21. Jacobson I, Catlett I, Marcellin P et al. 1369 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J. Hepatol. 54, S542-S543 (2011).
22. Poordad F, Lawitz E, Kowdley K et al. 1399 12-week interferon-free regimen of abt-450/r+ abt-333+ ribavirin achieved svr12 in more than 90% of treatment-naive hcv genotype-1-infected subjects and 47% of previous nonresponders. J. Hepatol. 56, S549-S550 (2012).
23. Zeuzem S, Soriano V, Asselah T et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369(7), 630-639 (2013).
24. Kwo PNG, Nahass R, Bernstein D et al. A Phase 3, Randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. J. Hepatol. 62(Suppl. 2), S270 (2015).
25. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59(6), 2083-2091 (2014).
26. Bochud PY, Bibert S, Kutalik Z et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55(2), 384-394 (2012).
27. Abe H, Ochi H, Maekawa T et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 53(3), 439-443 (2010).
28. Noureddin M, Wright EC, Alter HJ et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58(5), 1548-1557 (2013).
29. Rembeck K, Alsio A, Christensen PB et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 7(1), e29370 (2012).
30. Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Laging M. Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes. Hepatology 56(1), 394 (2012).
31. Ydreborg M, Westin J, Rembeck K et al. Impact of Il28brelated single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS ONE 8(11), e80172 (2013).
32. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661-1669 (2006).
33. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 46(6), 999-1008 (2007).
34. Abid K, Pazienza V, De Gottardi A et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J. Hepatol. 42(5), 744-751 (2005).
35. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 46(6), 999-1008 (2007).
36. Abid K, Pazienza V, De Gottardi A et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J. Hepatol. 42(5), 744-751 (2005).
37. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 37(6), 837-842 (2002).
38. Metz P, Reuter A, Bender S, Bartenschlager R. Interferonstimulated genes and their role in controlling hepatitis C virus. J. Hepatol. 59(6), 1331-1341 (2013).
39. Alberts B JA, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology Of The Cell, Fouth Edition. Garland Science, NY, USA, 884-886 (2002).
40. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3), 1021-1031 (2011).
41. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2), 499-509 (2010).
42. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45(2), 164-171 (2013).
43. Terczynska-Dyla E, Bibert S, Duong FH et al. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat. Commun. 5, 5699 (2014).
44. Hamming OJ, Terczynska-Dyla E, Vieyres G et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32(23), 3055-3065 (2013).
45. Jouvin-Marche E, Macek Jilkova Z, Thelu MA et al. Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. J. Infect. Dis. 209(12), 1907-1915 (2014).
46. Maeda T, Sumi S, Ueta A et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol. Genet. Metab. 85(4), 271-279 (2005).
47. Shipkova M, Lorenz K, Oellerich M, Wieland E, Von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin. Chem. 52(2), 240-247 (2006).
48. Lin S, Mclennan AG, Ying K et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J. Biol. Chem. 276(22), 18695-18701 (2001).
49. Chanda PK, Roy J, Banerjee AK. In vitro synthesis of genome length complementary RNA of vesicular stomatitis virus in the presence of inosine 5'-triphosphate. Virology 129(1), 225-229 (1983).
50. Simone PD, Pavlov YI, Borgstahl GE. ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics. Mutat. Res. 753(2), 131-146 (2013).
51. Mohandas T, Sparkes RS, Passage MB, Sparkes MC, Miles JH, Kaback MM. Regional mapping of ADA and ITP on human chromosome 20: cytogenetic and somatic cell studies in an X/20 translocation. Cytogenet. Cell Genet. 26(1), 28-35 (1980).
52. Sumi S, Marinaki AM, Arenas M et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111(4-5), 360-367 (2002).
53. Vanderheiden BS. Genetic studies of human erythrocyte inosine triphosphatase. Biochem. Genet. 3(3), 289-297 (1969).
54. Stocco G, Cheok MH, Crews KR et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85(2), 164-172 (2009).
55. Waisertreiger IS, Menezes MR, Randazzo J, Pavlov YI. Elevated levels of DNA strand breaks induced by a base analog in the human cell line with the P32T ITPA variant. J. Nucleic Acids. 2010, pii:872180 (2010).
56. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464(7287), 405-408 (2010).
57. Eskesen AN, Melum E, Moghaddam A et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur. J. Gastroenterol. Hepatol. 24(8), 890-896 (2012).
58. Clark PJ, Aghemo A, Degasperi E et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J. Viral Hepat. 20(12), 858-866 (2013).
59. Thompson AJ, Santoro R, Piazzolla V et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53(2), 389-395 (2011).
60. Ogawa E, Furusyo N, Kajiwara E et al. Comparative safety study on severe anemia by simeprevir-versus telaprevirbased triple therapy for chronic hepatitis C. J. Gastroenterol. Hepatol. doi:10. 1111/jgh. 12945 (2015) (Epub ahead of print).
61. Asselah T, Zeuzem S, Soriano V et al. 1186 itpa gene variants predict hemolytic ribavirin induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in sound-C2. J. Hepatol. 58, S482 (2013).
62. Thompson AJ, Clark PJ, Singh A et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J. Hepatol. 56(2), 313-319 (2012).
63. De Franceschi L, Fattovich G, Turrini F et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31(4), 997-1004 (2000).
64. Hitomi Y, Cirulli ET, Fellay J et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 140(4), 1314-1321 (2011).
65. Rembeck K, Waldenstrom J, Hellstrand K et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology 59(6), 2131-2139 (2014).
66. Holmes JA, Roberts SK, Ali RJ et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology 59(6), 2152-2160 (2014).
67. Kurosaki M, Tanaka Y, Tanaka K et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir. Ther. 16(5), 685-694 (2011).
68. He S, Mcphaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285(9), 6706-6715 (2010).
69. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40(12), 1461-1465 (2008).
70. Huang Y, He S, Li JZ et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl Acad. Sci. USA 107(17), 7892-7897 (2010).
71. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51(4), 1209-1217 (2010).
72. Speliotes EK, Butler JL, Palmer CD et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52(3), 904-912 (2010).
73. Stickel F, Buch S, Lau K et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53(1), 86-95 (2011).
74. Corradini SG, Burza MA, Molinaro A, Romeo S. Patatinlike phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 53(5), 1776; author reply 1777 (2011).
75. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53(3), 791-799 (2011).
76. Trepo E, Pradat P, Potthoff A et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54(1), 60-69 (2011).
77. Cai T, Dufour JF, Muellhaupt B et al. Viral genotypespecific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J. Hepatol. 55(3), 529-535 (2011).
78. Valenti L, Aghemo A, Stattermayer AF et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol. Ther. 35(12), 1434-1442 (2012).
79. Pirazzi C, Adiels M, Burza MA et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 57(6), 1276-1282 (2012).
80. Kumari M, Schoiswohl G, Chitraju C et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 15(5), 691-702 (2012).
81. Burza MA, Molinaro A, Attilia ML et al. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int. 34(4), 514-520 (2014).
82. Kollerits B, Coassin S, Beckmann ND et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum. Mol. Genet. 18(23), 4669-4676 (2009).
83. Rembeck K, Maglio C, Lagging M et al. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med. Genet. 13, 82 (2012).